Potentially repurposable drugs for schizophrenia identified from its interactome

[cjm]

Link to sci-hub full study: Potentially repurposable drugs for schizophrenia identified from its interactome

"In summary, clinical trial data, network-based analyses and literature review support the biological validity of 9 out of the 12 drugs proposed to be repurposable for schizophrenia, namely, acetazolamide, alfacalcidol, amiloride, antazoline, cinnarizine, cromoglicic acid, danazol, miconazole and tetracycline."

"Cromoglicic acid​

Cromoglicic acid is being tested in clinical trials for its efficacy in Alzheimer’s disease. It has been reported that cromoglicic acid in combination with ibuprofen reduces the levels of amyloid-beta protein levels, a pathological biomarker in Alzheimer’s disease, and promotes a neuroprotective state by activating microglia and inducing phagocytosis of amyloid-beta proteins 59. Based on this work, cromoglicic acid has been considered for further study by our clinical collaborators and is currently in clinical trials (ClinicalTrials.gov Identifier: NCT03794076)."

[full study cited: Cromolyn Reduces Levels of the Alzheimer’s Disease-Associated Amyloid β-Protein by Promoting Microglial Phagocytosis, value uncertain]

Cromoglicic acid, also known as cromolyn sodium or Nasalcrom, a "mast cell blocker."

I am very curious about why it works! The onset of action is not 2-3 weeks like some say, it is almost immediate, especially if administered in an enema (personal observation).

 

[cjm]

Cromolyn sodium is from a family of "anti-allergic" compounds called cromones. It is effective in "non-allergic settings" as well.

It is compared to ketotifen, a Peat antihistamine recommendation.

"When tested, ketotifen was found to have the same effect on the Anx-A1 system as nedocromil and cromoglycate suggesting a commonality of mechanisms of action (Sinniah et al., 2016). An important speculation is that all H1 antagonists with this additional action may have a secondary pharmacology as PP2A inhibitors and, if so, this could be a beneficial therapeutic screen to evaluate this property."

The Anti-allergic Cromones: Past, Present, and Future.

 

[cjm]

Cromolyn has endotoxin-protective effect in mast cell-deficient mice:

"this concentration of cromolyn (100 mg/kg) also inhibited LPS-induced TNF production in genetically mast cell-deficient C57BL/6-KitW-sh/W-sh mice in vivo."

Evidence questioning cromolyn’s effectiveness and selectivity as a ‘mast cell stabilizer’ in mice